Literature DB >> 9335507

Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling.

A Nakao1, M Afrakhte, A Morén, T Nakayama, J L Christian, R Heuchel, S Itoh, M Kawabata, N E Heldin, C H Heldin, P ten Dijke.   

Abstract

TGF-beta signals from the membrane to the nucleus through serine/threonine kinase receptors and their downstream effectors, termed SMAD proteins. The activated TGF-beta receptor induces phosphorylation of two such proteins, Smad2 and Smad3, which form hetero-oligomeric complex(es) with Smad4/DPC4 that translocate to the nucleus, where they then regulate transcriptional responses. However, the mechanisms by which the intracellular signals of TGF-beta are switched off are unclear. Here we report the identification of Smad7, which is related to Smad6. Transfection of Smad7 blocks responses mediated by TGF-beta in mammalian cells, and injection of Smad7 RNA into Xenopus embryos blocks activin/TGF-beta signalling. Smad7 associates stably with the TGF-beta receptor complex, but is not phosphorylated upon TGF-beta stimulation. TGFbeta-mediated phosphorylation of Smad2 and Smad3 is inhibited by Smad7, indicating that the antagonistic effect of Smad7 is exerted at this important regulatory step. TGF-beta rapidly induces expression of Smad7 mRNA, suggesting that Smad7 may participate in a negative feedback loop to control TGF-beta responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9335507     DOI: 10.1038/39369

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  502 in total

1.  Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase.

Authors:  Y Zhang; C Chang; D J Gehling; A Hemmati-Brivanlou; R Derynck
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

Review 2.  Transcriptional control by the TGF-beta/Smad signaling system.

Authors:  J Massagué; D Wotton
Journal:  EMBO J       Date:  2000-04-17       Impact factor: 11.598

Review 3.  Vascularization of the developing chick limb bud: role of the TGFbeta signalling pathway.

Authors:  Neil Vargesson
Journal:  J Anat       Date:  2003-01       Impact factor: 2.610

4.  Trigenic neural crest-restricted Smad7 over-expression results in congenital craniofacial and cardiovascular defects.

Authors:  Sunyong Tang; Paige Snider; Antony B Firulli; Simon J Conway
Journal:  Dev Biol       Date:  2010-05-08       Impact factor: 3.582

5.  BF-1 interferes with transforming growth factor beta signaling by associating with Smad partners.

Authors:  C Dou; J Lee; B Liu; F Liu; J Massague; S Xuan; E Lai
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

6.  Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB.

Authors:  R P Nagarajan; F Chen; W Li; E Vig; M A Harrington; H Nakshatri; Y Chen
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

7.  Negative feedback in the bone morphogenetic protein 4 (BMP4) synexpression group governs its dynamic signaling range and canalizes development.

Authors:  Malte Paulsen; Stefan Legewie; Roland Eils; Emil Karaulanov; Christof Niehrs
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-01       Impact factor: 11.205

Review 8.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors:  Li Yang; Yanli Pang; Harold L Moses
Journal:  Trends Immunol       Date:  2010-06-01       Impact factor: 16.687

Review 9.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

10.  Genetic susceptibility to interstitial pulmonary fibrosis in mice induced by vanadium pentoxide (V2O5).

Authors:  Dianne M Walters; Kevin M White; Ushma Patel; Martin J Davis; Roberta M Veluci-Marlow; Solomon Raju Bhupanapadu Sunkesula; James C Bonner; Jessica R Martin; Wes Gladwell; Steven R Kleeberger
Journal:  FASEB J       Date:  2013-11-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.